记忆增强药物市场 - 全球产业规模、份额、趋势、机会和预测，按药物类别、给药途径、配销通路、地区和竞争细分，2020-2030 年预测

2024 年全球记忆增强药物市场价值为 73.2 亿美元，预计到 2030 年将达到 99.5 亿美元，预测期内的年复合成长率(CAGR) 为 5.21%。这个市场是更广泛的认知健康和神经病学领域的一个子集，主要关注旨在改善记忆力、认知功能和整体大脑健康的药物和补充剂。市场扩张的动力在于认知障碍盛行率的上升、人口老化以及对认知健康的日益关注。

主要市场驱动因素

1. 人口老化

主要市场挑战

1. 监管和安全问题

主要市场趋势

1. 越来越重视认知健康与保健

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球记忆增强药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（胆碱酯酶抑制剂、智慧药物和认知增强剂、维生素和补充剂、其他）
  • 依给药途径（口服、注射、外用）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美记忆增强药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲记忆增强药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区记忆增强药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美记忆增强药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲记忆增强药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Pfizer Inc.
• UCB SA
• Takeda Pharmaceutical Company Limited
• SANOCHEMIA Pharmazeutika GmbH
• AbbVie Inc.
• Novartis AG
• Alkem Laboratories Ltd.
• Intas Pharmaceutical Ltd.
• Novartis AG
• Otsuka Holdings Co., Ltd.

第 15 章：策略建议

第16章 调査会社について・免责事项

The global Memory Enhancement Drugs Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 9.95 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.21% during the forecast period. This market is a subset of the broader cognitive health and neurology sectors, primarily focusing on pharmaceuticals and supplements aimed at improving memory, cognitive function, and overall brain health. The market's expansion is driven by the rising prevalence of cognitive disorders, an aging population, and a growing focus on cognitive well-being.

Key Market Drivers

1. Aging Population

The aging global population is a significant driver in the memory enhancement drugs market. As individuals age, they become more susceptible to cognitive decline and neurodegenerative diseases such as Alzheimer's and dementia, increasing the demand for memory-enhancing solutions.

• Rising Proportion of Elderly: The demographic shift toward an aging population is a key factor propelling the demand for memory enhancement drugs. This shift is attributed to lower birth rates and higher life expectancy. According to the World Health Organization, by 2050, the global population aged 60 and above is expected to double to 2.1 billion, with the number of people aged 80 and older tripling from 2020 to 2050, reaching 426 million.

Key Market Challenges

1. Regulatory and Safety Concerns

A significant challenge facing the market is the lack of sufficient scientific evidence supporting the long-term safety and efficacy of many memory enhancement drugs. Numerous products, especially those marketed as over-the-counter supplements or off-label drugs, do not undergo rigorous clinical trials to validate their claims.

• Regulatory Gaps: In many regions, inadequate regulation allows certain products to enter the market without comprehensive testing or quality control. This exposes consumers to potential risks from ineffective or harmful substances. The lack of sufficient regulation also results in insufficient consumer awareness regarding potential risks, leading to misuse or adverse effects.

Key Market Trends

1. Growing Focus on Cognitive Health and Wellness

There is a noticeable shift towards preventive healthcare, with an increasing emphasis on maintaining cognitive health throughout life. As people become more aware of the importance of cognitive function for overall well-being, they are actively seeking ways to optimize memory, mental clarity, and brain health at all stages of life. This shift has led to greater interest in both traditional and innovative methods for enhancing cognitive performance.

• A 2021 study involving 44 healthy participants aged 18 to 36 showed that those who took prucalopride performed significantly better in memory tests compared to a placebo group. Functional MRI scans revealed enhanced brain activity, particularly in regions related to memory, including the hippocampus and the right angular gyrus.

Key Market Players

• Pfizer Inc.
• UCB S.A.
• Takeda Pharmaceutical Company Limited
• SANOCHEMIA Pharmazeutika GmbH
• AbbVie Inc.
• Novartis AG
• Alkem Laboratories Ltd.
• Intas Pharmaceutical Ltd.
• Otsuka Holdings Co., Ltd.

Market Segmentation

The Global Memory Enhancement Drugs Market is segmented as follows:

1. By Drug Class

• Cholinesterase Inhibitors
• Smart Drugs and Cognitive Enhancers
• Vitamins and Supplements
• Others

2. By Route of Administration

• Oral
• Injectable
• Topical

3. By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

4. By Region

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

The report provides detailed analysis of the major players in the global Memory Enhancement Drugs Market.

Available Customizations

TechSci Research offers customization options for this report, including the following:

• Company Information: In-depth profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Memory Enhancement Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Cholinesterase Inhibitors, Smart Drugs and Cognitive Enhancers, Vitamins and Supplements, Others)
  • 5.2.2. By Route of Administration (Oral, Injectable, Topical)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Memory Enhancement Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Memory Enhancement Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Memory Enhancement Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Memory Enhancement Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Memory Enhancement Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Memory Enhancement Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Memory Enhancement Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Memory Enhancement Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Memory Enhancement Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Memory Enhancement Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Memory Enhancement Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Memory Enhancement Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Memory Enhancement Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Memory Enhancement Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Memory Enhancement Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Memory Enhancement Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Memory Enhancement Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Memory Enhancement Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Memory Enhancement Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Memory Enhancement Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Memory Enhancement Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Memory Enhancement Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Memory Enhancement Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Memory Enhancement Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. UCB S.A.
• 14.3. Takeda Pharmaceutical Company Limited
• 14.4. SANOCHEMIA Pharmazeutika GmbH
• 14.5. AbbVie Inc.
• 14.6. Novartis AG
• 14.7. Alkem Laboratories Ltd.
• 14.8. Intas Pharmaceutical Ltd.
• 14.9. Novartis AG
• 14.10. Otsuka Holdings Co., Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer